Last reviewed · How we verify
Hypotensives
Hypotensives is a Small molecule drug developed by Abd-Elazeem Abd-Elhameed Elbakry. It is currently in Phase 1 development. Also known as: deliberate hypotension.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Hypotensives |
|---|---|
| Also known as | deliberate hypotension |
| Sponsor | Abd-Elazeem Abd-Elhameed Elbakry |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nutritional Ketosis Marfan (NA)
- CART BP Pro-Guided Blood Pressure Management for Uncontrolled Hypertension (NA)
- Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial (NA)
- Effect of Hypertensive Drugs on Root Caries Among Senior Patients in Cairo University
- Orthostatic And Postprandial Hypotension In Hospitalized Older Adults (HOPE65)
- Use of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women
- CENtral Blood Pressure Targeting: A Pragmatic RAndomized Pilot triaL in Advanced Chronic Kidney Disease (NA)
- BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hypotensives CI brief — competitive landscape report
- Hypotensives updates RSS · CI watch RSS
- Abd-Elazeem Abd-Elhameed Elbakry portfolio CI
Frequently asked questions about Hypotensives
What is Hypotensives?
Who makes Hypotensives?
Is Hypotensives also known as anything else?
What development phase is Hypotensives in?
Related
- Manufacturer: Abd-Elazeem Abd-Elhameed Elbakry — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: deliberate hypotension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing